福安藥業(300194.SZ):鹽酸昂丹司瓊注射液通過一致性評價
格隆匯6月29日丨福安藥業(300194.SZ)宣佈,公司全資子公司天衡藥業於近日收到國家藥監局核准簽發的藥品補充申請批准通知書,其產品鹽酸昂丹司瓊注射液(4ml:8mg)通過了仿製藥質量和療效一致性評價。
鹽酸昂丹司瓊注射液主要適用於控制癌症化療和放射治療引起的噁心和嘔吐;亦適用於預防和手術後噁心嘔吐。
截止目前,持有該產品生產批文的的廠家較多,天衡藥業該產品通過一致性評價,將進一步提升公司該產品的技術水平,有利於提高產品的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.